Mirabegron Zentiva (Mirabegron)

The drug activates β3‑adrenergic receptors on the bladder’s detrusor muscle. This activation relaxes the muscle, allowing the bladder to hold more urine and decreasing the frequency of involuntary contractions that cause urgency.

The dosage of Mirabegron is individualized by the prescribing clinician based on the patient’s condition, renal and hepatic function, and response to therapy. The prescriber determines the appropriate strength and titration schedule.

Safety data for Mirabegron during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) and does not have the anticholinergic side‑effects such as dry mouth and constipation that are common with antimuscarinic drugs. It may be used alone or in combination with antimuscarinics for patients who need additional symptom control.

Store Mirabegron tablets at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Mirabegron is taken orally, usually as a whole tablet swallowed with water. It is generally taken once daily, with or without food, as directed by the prescribing clinician.

Patients should be alert for severe hypertension, urinary retention that may require catheterisation, and signs of angle‑closure glaucoma such as eye pain, blurred vision, or halos around lights. Any of these symptoms warrant immediate medical attention.

Mirabegron is contraindicated in individuals with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to the drug. Caution is also advised for patients with a history of urinary retention or narrow‑angle glaucoma.